



सत्यमेव जयते

Department of Pharmaceuticals
Government of India



Program: India Medical Device Conference -2019
18th – 19th February 2019 | The Lalit Ashok, Bangalore
Theme – Accelerating Growth to Achieve Universal Healthcare

DATE / TIME	EVENT	
Day 1: Monday, 18 February 2019		
0930-1130	Inaugural Session & Awards: India Pharma 2019 & India Medical Device 2019	
	0830-0930	Registration
	0930-1130	Inaugural Session
1130-1200	Tea Break	
1200-1330	PLENERY SESSION - 1 DIAGNOSTICS ECOSYSTEM IN INDIA: ENSURING ACCESS, QUALITY & INNOVATION FOR ALL	
	<p>Session Brief: This session should cover role of IVDs/ IVD industry from Access, Quality and innovation standpoint and how over years access has been increased by stable prices and extended reach to tier2-3 cities through lab networks and robust supply chain ensuring delivery, service and quality to last mile. Since the talk will be on the entire ecosystem – speakers can highlight the intricacies of a diagnostic supply chain and prevailing business models – its uniqueness and how the ecosystem is delicately balanced and prone to getting disturbed by irrational controls.</p>	
	<p>Chair: Prof Balram Bhargava, Secretary – DHR; Director General, ICMR Moderator: Mr Vikas Dandekar, Editor - Pharma and Healthcare, ET Prime ©</p>	
	<p>Panellists:</p> <p><u>Government Officials:</u></p> <ul style="list-style-type: none"> • Mr Jawaid Akhtar Principal Secretary - Health and FW Department, Government of Karnataka • Dr Mandeep K Bhandari, Joint Secretary, Ministry of Health & Family Welfare, Government of India • Ms Ritu Dhillon, Joint Secretary, Department of Pharmaceuticals; Member Secretary, NPPA, Government of India • Dr Madhur Gupta, Technical Officer-Pharmaceuticals – WHO India <p><u>Industry</u></p> <ul style="list-style-type: none"> • (Hony) Brig Dr Arvind Lal, Chair - FICCI Health Services Committee; CMD - Dr Lal PathLabs • Mr Saurabh Rajadhyax, Managing Director - Biomeriuex India Pvt. Ltd • Ms Veena Kohli, CEO - Vanguard Diagnostics © 	
1330-1430	Networking Lunch	
1430-1630	INDIA MEDICAL DEVICE 2019 CEO'S ROUNDTABLE (By Invitation Only)	
1430-1630 (Parallel)	Workshop on Sensitizing the Medical Device Industry on BIS Standardization	
1630-1645	Tea Break	

1645-1745	PLENERY SESSION – 2 PROMOTING MAKE IN INDIA: REVITALIZING EASE OF DOING BUSINESS
	<p>Session Brief:</p> <p><u>Track 1 - Strengthening Policy Framework for Med - Tech Sector</u> Discussion on the immediate need for a separate Act and policy governing medical devices sector in order to streamline regulation on various fronts and pricing mechanisms. Predictable evidence based policy environment a key for growth of the sector.</p> <p><u>Track 2- Ensuring Global Harmonization of Regulatory Standards and Regimen</u> Discuss on the need for global harmonization of regulatory standards and implementation of policies that promote access to world class standards compliant devices while tackling duplicity of testing requirements</p> <p><u>Track 3- Making Innovation the Cornerstone of Improving Healthcare</u> Discussion on challenges in access to innovative medical technologies in the country today and recommend approaches to address the conundrum between pricing and quality, me-too products and cutting -edge technology and why innovation needs to be at the centre of improving healthcare access and achieving UHC targets</p>
	<p>Chair: Mr Rajiv Aggarwal, Joint Secretary, Department of Industrial Policy & Promotion, Gol</p> <p>Moderator: Mr Madan Rohini Krishnan, Vice President, India Medtronic</p> <p>Panellists:</p> <p><u>Government Officials</u></p> <ul style="list-style-type: none"> • Ms Ritu Dhillon, Joint Secretary, Department of Pharmaceuticals; Member Secretary, NPPA, Government of India • Dr Mandeep K Bhandari, Joint Secretary, Ministry of Health & Family Welfare, Government of India • Ms Surina Rajan, Director General, Bureau of Indian Standards • Mr Alok Kumar, Advisor, NITI Aayog <p><u>Industry</u></p> <ul style="list-style-type: none"> • Mr Sashi Kumar V, Co-Chair-FICCI Medical Device Committee; MD, Phoenix Medical Systems (P) Ltd. • Mr Probir Das, Regional Representative - India and Asia Pacific & Chairman, Terumo Asia Holding © • Mr Himanshu Baid, Managing Director, Poly Medicure Ltd. • Mr Nalinikanth Gollagunta, President & CEO, GE Healthcare & MD, Wipro GE Healthcare • Mr Prabal Chakraborty, Vice President & Managing Director, Boston Scientific India
1745-1800	Tea Break
1800-1930	JOINT CLOSED-DOOR SESSION: INTERNATIONAL REGULATORS INTERACTION WITH CEO'S OF PHARMACEUTICAL AND MEDICAL DEVICE INDUSTRY (By Invitation Only)
	<p>Session Brief:</p> <p>The session aims to provide a platform for Pharmaceutical and Med-tech CEOs to place their views on evolving international regulatory scenario. This is to enable Indian manufacturers faster access to international markets while at the same time allow international markets to harness the growth and export potential of Indian manufacturers.</p>
1930 onwards	Networking Dinner Hosted by Department of Pharmaceuticals, Govt. of India

Day 2: Tuesday, 19th February, 2019

1000 -1130	Session by WHO
1130 -1145	Tea Break
1145-1300	JOINT SESSION: DECODING APPLICATIONS OF ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL AND MEDICAL DEVICES INDUSTRY
1300-1400	Lunch
1400-1515	PLENERY SESSION - 4 ROAD TO UNIVERSAL HEALTHCARE THROUGH HEALTH TECHNOLOGY ASSESSMENT (HTA)
	<p>Session Brief:</p> <p><u>Track 1: Road to Universal Health Coverage in India: HTA as a Value Assessment Tool</u></p> <ul style="list-style-type: none"> • How is HTA in India different than other LMICs? What are the learnings which could be applied in India? • Will HTA help in value assessment or also deciding a price point for a product? • How HTA is connected to equity and benefits various strata of society at large? <p><u>Track 2: Universal Health Coverage and HTA: Healthcare Provider's perspective</u></p> <ul style="list-style-type: none"> • How does local HTA fit into the decision making process at a local level? • How would a hospital prioritize a list of the products, which would need local/hospital HTA as an addition to the national HTA findings of that product? <p><u>Track 3: Universal Health Coverage and HTA: Healthcare Regulator's perspective</u></p> <ul style="list-style-type: none"> • How does a product undergo a pan India evaluation in terms of data availability and quantitative assessment? • How does real world evidence from India shape HTAIn evaluations?
	<p>Chair: Prof Balram Bhargava, Secretary – DHR; Director General, ICMR Moderator: TBD</p>
	<p>Panellists:</p> <p><u>Government</u></p> <ul style="list-style-type: none"> • Dr Dinesh Arora, Deputy CEO, National Health Authority, Government of India • Mr V K Gauba, Joint Secretary - Department of Health Research (DHR), Ministry of Health & Family Welfare, Government of India • Dr Mohammad Ameel, Senior Consultant - National Health Systems Resource Centre (NHSRC) <p><u>Industry</u></p> <ul style="list-style-type: none"> • Ms Virginia Priest, Head - Health Economics and Reimbursement, Boston Scientific • Mr Pavan Mocherla, MD - India / South Asia, Becton Dickinson India Private Limited • Mr Pavan Choudary, Managing Director, Vygon India Pvt. Ltd. • Dr Sanjeev K. Singh, Medical Superintendent, Amrita School of Medicine, Kochi. • Dr Pinaki Ghosh, Manager Market Access & Health Economics, BBraun
1515-1530	Tea

1530 -1545	Keynote Address on Ayushman Bharat Dr Indu Bhushan , CEO - National Health Agency, Government of India; Secretary – Government of India
1545 – 1715	JOINT SESSION MED-TECH & PHARMACEUTICALS: GEARING UP FOR AYUSHMAN BHARAT
	<p>Session Brief:</p> <p><u>Track 1: The session would revolve around Ayushman Bharat, and how the entire ecosystem can move together towards Universal Healthcare.</u></p> <ul style="list-style-type: none"> • Role of Medical Technology & Pharmaceutical Industry • Learnings from AB-PMJAY and road ahead for gearing up to serve a population of 500 Million. • Role to be played by med tech and pharma sector in skilling and capacity building of healthcare professionals, doctors, physicians, nurses, technicians etc. and institutionalizing this initiative for constant up-skilling of capabilities in the healthcare system • Steps towards a more inclusive Universal Healthcare coverage—International best practices <p><u>Track 2: Enabling Med-Tech & Pharmaceuticals to Efficiently Serve Ayushman Bharat</u></p> <p>Ayushman Bharat’s roll out makes a promising start to expand the market size and fill the longstanding demand side gaps in the medical device industry. The next BIG question arises on the supply side preparedness to meet this rising demand. In this evolving backdrop, this session aims at deliberating the short/medium/ long term structural/ operational changes required to enable this industry to serve this most aspirational health scheme rolled out by GoI.</p>
	<p>Chair: Dr Indu Bhushan, CEO - National Health Authority, Government of India</p> <p>Moderator: Mr Badhri Iyenger, Chair - FICCI Medical Device Committee; Managing Director - South Asia & South East Asia, Smith & Nephew Healthcare Ltd. ©</p> <p>Panellists:</p> <p><u>Government Officials:</u></p> <ul style="list-style-type: none"> • Mr Jawaid Akhtar, Principal Secretary - Health and FW Department, Government of Karnataka • Ms Shubhra Singh, Chairperson, NPPA • Mr Arun Singhal, Additional Secretary, Ministry of Health & Family Welfare, Government of India • Mr Sanjeeva Kumar, AS & DG (CGHS) and Additional Secretary (Health), Ministry of Health & Family Welfare, Government of India <p><u>Industry</u></p> <ul style="list-style-type: none"> • Dr Alok Roy, Co-Chair – FICCI Health Services Committee ; Chairman, Medica Hospitals © • Mr Sanjay Bhutani, Managing Director – India & SAARC, Bausch & Lomb ©
1715	Close